State of New Jersey Common Pension Fund D Acquires 4,475 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

State of New Jersey Common Pension Fund D raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 22.0% in the fourth quarter, Holdings Channel reports. The firm owned 24,804 shares of the company’s stock after purchasing an additional 4,475 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Krystal Biotech were worth $3,077,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in Krystal Biotech by 111.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 718 shares of the company’s stock valued at $83,000 after purchasing an additional 379 shares during the period. Fox Run Management L.L.C. bought a new position in Krystal Biotech in the 3rd quarter valued at $219,000. Prime Capital Investment Advisors LLC bought a new position in Krystal Biotech in the 4th quarter valued at $310,000. Graham Capital Management L.P. bought a new position in Krystal Biotech in the 3rd quarter valued at $330,000. Finally, Confluence Wealth Services Inc. grew its stake in Krystal Biotech by 20.7% in the 3rd quarter. Confluence Wealth Services Inc. now owns 2,920 shares of the company’s stock valued at $339,000 after purchasing an additional 500 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Up 0.8 %

NASDAQ:KRYS opened at $156.88 on Friday. The business’s 50-day moving average price is $164.33 and its two-hundred day moving average price is $131.69. Krystal Biotech, Inc. has a twelve month low of $82.09 and a twelve month high of $189.97. The stock has a market cap of $4.47 billion, a P/E ratio of 1,961.25 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.82. The business had revenue of $42.14 million during the quarter, compared to analysts’ expectations of $27.43 million. During the same period in the previous year, the business earned ($1.25) EPS. On average, equities research analysts expect that Krystal Biotech, Inc. will post 1.89 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on KRYS. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Guggenheim upped their price target on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Citigroup increased their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a report on Monday, April 22nd. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and an average price target of $171.00.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the transaction, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The disclosure for this sale can be found here. Insiders have sold a total of 38,087 shares of company stock valued at $6,210,591 in the last 90 days. Corporate insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).